197 related articles for article (PubMed ID: 2529028)
21. Retinol-binding protein secretion from the liver of N-(4-hydroxyphenyl) retinamide-treated rats.
Ritter SJ; Smith JE
Biochim Biophys Acta; 1996 Jun; 1290(2):157-64. PubMed ID: 8645719
[TBL] [Abstract][Full Text] [Related]
22. Investigation of oral fenretinide for treatment of geographic atrophy in age-related macular degeneration.
Mata NL; Lichter JB; Vogel R; Han Y; Bui TV; Singerman LJ
Retina; 2013 Mar; 33(3):498-507. PubMed ID: 23023528
[TBL] [Abstract][Full Text] [Related]
23. N-(4-hydroxyphenyl)retinamide in the chemoprevention of squamous metaplasia and dysplasia of the bronchial epithelium.
Kurie JM; Lee JS; Khuri FR; Mao L; Morice RC; Lee JJ; Walsh GL; Broxson A; Lippman SM; Ro JY; Kemp BL; Liu D; Fritsche HA; Xu X; Lotan R; Hong WK
Clin Cancer Res; 2000 Aug; 6(8):2973-9. PubMed ID: 10955773
[TBL] [Abstract][Full Text] [Related]
24. Retinoid receptor-dependent and independent biological activities of novel fenretinide analogues and metabolites.
Sabichi AL; Xu H; Fischer S; Zou C; Yang X; Steele VE; Kelloff GJ; Lotan R; Clifford JL
Clin Cancer Res; 2003 Oct; 9(12):4606-13. PubMed ID: 14555536
[TBL] [Abstract][Full Text] [Related]
25. Long-term effects of fenretinide, a retinoic acid derivative, on the insulin-like growth factor system in women with early breast cancer.
Decensi A; Johansson H; Miceli R; Mariani L; Camerini T; Cavadini E; Di Mauro MG; Barreca A; Gonzaga AG; Diani S; Sandri MT; De Palo G; Formelli F
Cancer Epidemiol Biomarkers Prev; 2001 Oct; 10(10):1047-53. PubMed ID: 11588130
[TBL] [Abstract][Full Text] [Related]
26. Pilot trial of the safety, tolerability, and retinoid levels of N-(4-hydroxyphenyl) retinamide in combination with tamoxifen in patients at high risk for developing invasive breast cancer.
Conley B; O'Shaughnessy J; Prindiville S; Lawrence J; Chow C; Jones E; Merino MJ; Kaiser-Kupfer MI; Caruso RC; Podgor M; Goldspiel B; Venzon D; Danforth D; Wu S; Noone M; Goldstein J; Cowan KH; Zujewski J
J Clin Oncol; 2000 Jan; 18(2):275-83. PubMed ID: 10637240
[TBL] [Abstract][Full Text] [Related]
27. Liquid chromatography method for quantifying N-(4-hydroxyphenyl)retinamide and N-(4-methoxyphenyl)retinamide in tissues.
Vratilova J; Frgala T; Maurer BJ; Patrick Reynolds C
J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Sep; 808(2):125-30. PubMed ID: 15261805
[TBL] [Abstract][Full Text] [Related]
28. 4-oxo-fenretinide, a recently identified fenretinide metabolite, induces marked G2-M cell cycle arrest and apoptosis in fenretinide-sensitive and fenretinide-resistant cell lines.
Villani MG; Appierto V; Cavadini E; Bettiga A; Prinetti A; Clagett-Dame M; Curley RW; Formelli F
Cancer Res; 2006 Mar; 66(6):3238-47. PubMed ID: 16540676
[TBL] [Abstract][Full Text] [Related]
29. N-(4-Hydroxyphenyl)retinamide and nitric oxide pro-drugs exhibit apoptotic and anti-invasive effects against bone metastatic breast cancer cells.
Simeone AM; Colella S; Krahe R; Johnson MM; Mora E; Tari AM
Carcinogenesis; 2006 Mar; 27(3):568-77. PubMed ID: 16199439
[TBL] [Abstract][Full Text] [Related]
30. Identification of the fenretinide metabolite 4-oxo-fenretinide present in human plasma and formed in human ovarian carcinoma cells through induction of cytochrome P450 26A1.
Villani MG; Appierto V; Cavadini E; Valsecchi M; Sonnino S; Curley RW; Formelli F
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6265-75. PubMed ID: 15448016
[TBL] [Abstract][Full Text] [Related]
31. Ocular effects of fenretinide, a vitamin A analog, in a chemoprevention trial of bladder cancer.
Baglietto L; Torrisi R; Arena G; Tosetti F; Gonzaga AG; Pasquetti W; Robertson C; Decensi A
Cancer Detect Prev; 2000; 24(4):369-75. PubMed ID: 11059568
[TBL] [Abstract][Full Text] [Related]
32. Tolerability of the synthetic retinoid Fenretinide (HPR).
Costa A; Malone W; Perloff M; Buranelli F; Campa T; Dossena G; Magni A; Pizzichetta M; Andreoli C; Del Vecchio M
Eur J Cancer Clin Oncol; 1989 May; 25(5):805-8. PubMed ID: 2525470
[TBL] [Abstract][Full Text] [Related]
33. Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide.
Costa A; Formelli F; Chiesa F; Decensi A; De Palo G; Veronesi U
Cancer Res; 1994 Apr; 54(7 Suppl):2032s-2037s. PubMed ID: 8137334
[TBL] [Abstract][Full Text] [Related]
34. Fenretinide therapy in prostate cancer: effects on tissue and serum retinoid concentration.
Thaller C; Shalev M; Frolov A; Eichele G; Thompson TC; Williams RH; Dillioglugil O; Kadmon D
J Clin Oncol; 2000 Nov; 18(22):3804-8. PubMed ID: 11078493
[TBL] [Abstract][Full Text] [Related]
35. Enhanced inhibition of mammary carcinogenesis by combined treatment with N-(4-hydroxyphenyl)retinamide and ovariectomy.
McCormick DL; Mehta RG; Thompson CA; Dinger N; Caldwell JA; Moon RC
Cancer Res; 1982 Feb; 42(2):508-12. PubMed ID: 6459843
[TBL] [Abstract][Full Text] [Related]
36. Long-term tolerability of fenretinide (4-HPR) in breast cancer patients.
Rotmensz N; De Palo G; Formelli F; Costa A; Marubini E; Campa T; Crippa A; Danesini GM; Delle Grottaglie M; Di Mauro MG
Eur J Cancer; 1991; 27(9):1127-31. PubMed ID: 1835622
[TBL] [Abstract][Full Text] [Related]
37. Plasma retinol levels and side effects following high-dose retinyl acetate in breast cancer patients.
Resasco M; Canobbio L; Trave F; Valenti G; Mazzoni A; Canti G; Boccardo F; Nicolin A
Anticancer Res; 1988; 8(6):1319-23. PubMed ID: 3218964
[TBL] [Abstract][Full Text] [Related]
38. Decrease in drug accumulation and in tumour aggressiveness marker expression in a fenretinide-induced resistant ovarian tumour cell line.
Appierto V; Cavadini E; Pergolizzi R; Cleris L; Lotan R; Canevari S; Formelli F
Br J Cancer; 2001 Jun; 84(11):1528-34. PubMed ID: 11384104
[TBL] [Abstract][Full Text] [Related]
39. NTP Toxicology and Carcinogenesis Studies of 4,4'-Thiobis(6- t -butyl- m -cresol) (CAS No. 96-69-5) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1994 Dec; 435():1-288. PubMed ID: 12595928
[TBL] [Abstract][Full Text] [Related]
40. N-(4-Hydroxyphenyl)retinamide is more potent than other phenylretinamides in inhibiting the growth of BRCA1-mutated breast cancer cells.
Simeone AM; Deng CX; Kelloff GJ; Steele VE; Johnson MM; Tari AM
Carcinogenesis; 2005 May; 26(5):1000-7. PubMed ID: 15695235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
